A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

• Status: WITHDRAWN
• Trial end date: 2026-01-15

Summary

To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).

• Phase: PHASE1

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Microbiota